Package Leaflet: Information for the Patient
Rivaroxaban Cipla 10 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
This medication contains the active substance rivaroxaban and is used in adults to:
This medication belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Cipla
Do not take rivaroxaban and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be careful with rivaroxaban
Inform your doctor if you have any of these situationsbefore taking this medication. Your doctor will decide whether you should be treated with this medication and whether you should be kept under closer observation.
If you need surgery
Children and adolescents
This medication is not recommended for children under 18 years of age.There is not enough information about its use in children and adolescents.
Other medications and Rivaroxaban Cipla
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of rivaroxaban may be increased. Your doctor will decide whether you should be treated with this medication and whether you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they will recommend that you also use an ulcer prevention treatment.
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of rivaroxaban may be decreased. Your doctor will decide whether you should be treated with this medication and whether you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take this medication if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking this medication. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (a frequent side effect) or fainting (a rare side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban Cipla contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the administration instructions of this medication exactly as indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again.
What dose to take
After at least 6 months of treatment for blood clots, the recommended dose is one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed rivaroxaban 10 mg once a day.
Swallow the tablet, preferably with water.
This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple puree, immediately before taking it.
If necessary, your doctor may also administer the crushed tablet through a gastric tube.
Remember to carry your patient information card with you at all times. Inform the doctor and dentist treating you that you are taking rivaroxaban.
When to take Rivaroxaban Cipla
Take one tablet every day, until your doctor tells you to stop.
Try to take one tablet at the same time every day, to help you remember. The doctor will decide how long you should continue treatment.
To prevent the formation of blood clots in the veins after hip or knee replacement surgery:
Take the first tablet 6 to 10 hours after surgery.
If you have undergone major hip surgery, you will usually take tablets for 5 weeks.
If you have undergone major knee surgery, you will usually take tablets for 2 weeks.
If you take more Rivaroxaban Cipla than you should
Contact your doctor immediately if you have taken too much rivaroxaban. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban Cipla
If you forget to take a dose, take it as soon as you remember. Take the next tablet the next day and, after that, take one tablet every day, as usual.
Do not take a double dose to make up for forgotten doses.
If you stop taking Rivaroxaban Cipla
Do not stop treatment with rivaroxaban without first talking to your doctor, as rivaroxaban prevents the development of a serious condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone gets them.
Like other similar medications to reduce blood clotting, rivaroxaban can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be apparent.
Tell your doctor immediately if you experience any of the following symptoms:
Your doctor will decide whether to keep you under closer observation or change your treatment.
The frequency of these side effects is very rare (affects up to 1 in 10,000 people).
The frequency of severe allergic reactions is very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible side effects
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister after “EXP”. The expiry date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Crushed tablets
Crushed tablets are stable in water or apple sauce for up to 4 hours.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Rivaroxaban Cipla
Tablet core: sodium croscarmellose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. See section 2 “Rivaroxaban Cipla contains lactose and sodium”.
Coating material: hypromellose 2910 (E 464), red iron oxide (E 172), macrogol (E 1521), titanium dioxide (E 171).
Appearance and package contents of the product
Rivaroxaban Cipla 10 mg film-coated tablets are pink, round, biconvex, 6.0 ± 0.20 mm in diameter, engraved with “10” on one side and smooth on the other.
They are available in PVC/PVDC/Aluminum blister packs packaged in boxes of 10, 14, 30, 56, 98, and 168 film-coated tablets.
Not all pack sizes may be marketed.
Along with the package leaflet of this medicine, a patient information card is included. This patient information card includes information that will be useful for patients and will alert other doctors that the patient is taking rivaroxaban. The patient should be advised to always carry this card with them.
Marketing authorization holder and manufacturer
Marketing authorization holder
Cipla Europe NV
De Keyserlei 58-60, Box-19,
2018, Antwerp,
Belgium
Manufacturer
Cipla Europe NV
De Keyserlei 58-60, Box-19,
2018, Antwerp,
Belgium
Or
Alterno AD D.O.O.,
Brnciceva ulica 29,
Ljubljana-Crnuce, 1231,
Slovenia
Local representative
Cipla Europe NV, branch in Spain,
C/Guzmán el Bueno, 133 Edificio Britannia,
28003, Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany: Rivaroxaban Cipla 10 mg Filmtabletten
Spain: Rivaroxabán Cipla 10 film-coated tablets EFG
Norway: Rivaroxaban Cipla
France: Rivaroxaban Cipla 10 mg Comprimé pelliculé
Italy: Rivaroxaban Cipla
Denmark: Rivaroxaban Cipla 10 mg filmovertrukne tabletter
Ireland: Rivaroxaban Azure 10 mg Film-Coated Tablets
Date of last revision of this package leaflet: November 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.